| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8439402 | European Journal of Cancer | 2018 | 9 Pages |
Abstract
In sSCC, dacomitinib showed activity similar to what was observed with anti-epidermal growth factor receptor agents, and durable clinical benefit was observed. Safety profile was comparable to previous experiences in other cancers. Molecular pt selection could improve therapeutic ratio.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
S. Cavalieri, F. Perrone, R. Miceli, P.A. Ascierto, L.D. Locati, C. Bergamini, R. Granata, S. Alfieri, C. Resteghini, D. Galbiati, A. Busico, N. Paielli, R. Patuzzo, A. Maurichi, G. Gallino, R. Ruggeri, L. Mariani, M. Palla, P. Bossi,